The problem of adverse drug reactions (ADR) development in psychopharmacotherapy is one of the current issues in the treatment of patients with schizophrenia. One of the most common ADRs when taking antipsychotics is the development of metabolic syndrome. This reduces the quality of life of patients and increases the risk of premature death of patients due to cardiovascular diseases. Markers of systemic inflammation are a predictor of the development of metabolic syndrome in patients with schizophrenia. One of these hematological coefficients is the  monocyte-to-lymphocyte ratio (MLR). Objective: to conduct a systematic review of scientific publications based on the relationship between MLR and metabolic syndrome in patients with schizophrenia. Methods: The initial search identified 120 articles from the Pubmed and ScienceDirect databases. The inclusion criterion for the study is the relationship between the MLR and metabolic syndrome in patients with schizophrenia. Result: Screening did not yield any publications suitable for systematic review.